Clinical Trial Update: Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

View source ↗

Summary

A clinical trial evaluating recombinant human interleukin-11 in combination with low-dose rituximab for immune thrombocytopenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Oprelvekin (oprelvekin)
• Rituximab (rituximab)

Snippet

Sponsor: Ming Hou | Conditions: Purpura, Thrombocytopenic, Idiopathic | Status: WITHDRAWN